← Leaderboards
David Jay Burkhart
Serendipity Pharmaceuticals, Inc.
$2,793,084
Attributed
$2,793,084
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $714.6K · FY2006–21$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,793,084 · 2
By mechanism
R01$2,693,084 · 1
R41$100,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantActive SitesAgonistAntibodiesAntigen-Presenting CellsAntigensBenchmarkingCathepsins BCellsCellular ImmunityChemical ConjugateConjugate VaccinesCostCytokineDendritic CellsDoseEarly EndosomeEffectivenessEndosomesExposure ToFamily SuidaeHa AntigenImmuneImmune Activation
Grant awards (5)
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy$644,035
R01 · FY2021 · AI · contact PI
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy$635,274
R01 · FY2020 · AI · contact PI
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy$714,601
R01 · FY2019 · AI · contact PI
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy$699,174
R01 · FY2018 · AI · contact PI
Plasmin-activated Prodrug Therapy for Pancreatic Cancer$100,000
R41 · FY2006 · CA · contact PI